Combined Effects of Metoprolol and Spironolactone in Dilated Cardiomyopathic Hamsters
Authors:
- Danielle PapeDPDanielle Pape
- Pascal GuilloPGPascal Guillo
- Marie-Paule RaméeMRMarie-Paule Ramée
- Eric BellissantEBEric Bellissant
- 1 October 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 40 (4) , 543-553
Abstract
The use of β-blockers reduces angiotensin II levels, but could not adequately suppress aldosterone production. Thus, the combination of a β-blocker with an aldosterone receptor antagonist could exert additive effects. The effects of metoprolol and spironolactone and their combination on hemodynamics and cardiac remodeling in cardiomyopathic hamsters (CMH) were investigated. The Bio TO-2 dilated strain of CMH was treated orally with metoprolol (10 mg/kg/day), spironolactone (20 mg/kg/day), or both according to a 2 × 2 factorial design (24 animals per group) from 120 days of age and during 120 days. As compared to corresponding untreated groups, metoprolol significantly decreased mean blood pressure (−7%), and metoprolol and spironolactone significantly increased cardiac output (18% and 19%, respectively), mesenteric blood flow (11% and 14%), and femoral blood flow (13% and 17%), and significantly decreased systemic (−24% and −15%), mesenteric (−14% and −13%) and femoral (−19% and −10%) vascular resistances. Metoprolol significantly increased renal blood flow (22%) and significantly decreased renal vascular resistance (−23%). Metoprolol and spironolactone significantly decreased the cavity area of the left ventricle (−21% and −32%, respectively) and the collagen density of the left (−36% and −39%) and right (−38% and −43%) ventricles. Although the combination did not induce stronger effects than each drug alone on the systemic and most regional hemodynamic variables, it did have a stronger effect on the cardiac remodeling (compared to control group: −24%, −34%, and −46% for the left ventricle cavity area, −33%, −35%, and −62% for collagen density in the left ventricle, and −52%, −57%, and −59% for collagen density in the right ventricle, respectively, in the metoprolol, spironolactone, and metoprolol + spironolactone groups). In CMH, metoprolol and spironolactone combined did not improve hemodynamics more than each drug alone, but did exert additive effects on cardiac remodeling.Keywords
This publication has 26 references indexed in Scilit:
- Hemodynamic and histomorphometric characteristics of dilated cardiomyopathy of Syrian hamsters (Bio TO-2 strain)Canadian Journal of Physiology and Pharmacology, 2001
- Aldosterone, a New Appreciation of Its Role in Heart FailurePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE IIThe Lancet, 2000
- Effects of Metoprolol CR in Patients With Ischemic and Dilated CardiomyopathyCirculation, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathyJournal of Internal Medicine, 1999
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Neurohumoral mechanisms involved in congestive heart failureThe American Journal of Cardiology, 1985
- Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscleLife Sciences, 1982